Compile Data Set for Download or QSAR
Report error Found 62 Enz. Inhib. hit(s) with all data for entry = 50021480
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225162((4R)-N-[2-(dimethylamino)ethyl]-1-({4-[(2-phenylbe...)
Affinity DataIC50: 2nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50065115(N-[4-(5H,11H-Benzo[e]pyrrolo[1,2-a][1,4]diazepine-...)
Affinity DataIC50: 5nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225163((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-met...)
Affinity DataIC50: 5nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225162((4R)-N-[2-(dimethylamino)ethyl]-1-({4-[(2-phenylbe...)
Affinity DataIC50: 8nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225166((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-eth...)
Affinity DataIC50: 8nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225167(N-(4-{[3'-(hydroxymethyl)-1,2,3,5-tetrahydrospiro[...)
Affinity DataIC50: 9nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225167(N-(4-{[3'-(hydroxymethyl)-1,2,3,5-tetrahydrospiro[...)
Affinity DataIC50: 9nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225159((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-met...)
Affinity DataIC50: 11nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225173((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]phenyl...)
Affinity DataIC50: 13nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225168(1-({4-[(2-phenylbenzene)amido]phenyl}carbonyl)-1,2...)
Affinity DataIC50: 14nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225172(methyl 1-({4-[(2-fluorobenzene)amido]phenyl}carbon...)
Affinity DataIC50: 15nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225167(N-(4-{[3'-(hydroxymethyl)-1,2,3,5-tetrahydrospiro[...)
Affinity DataIC50: 18nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225170(N-[4-({3'-[(methylamino)methyl]-1,2,3,5-tetrahydro...)
Affinity DataIC50: 18nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225160(1-({4-[(2-chloro-5-fluorobenzene)amido]-3-methoxyp...)
Affinity DataIC50: 19nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225168(1-({4-[(2-phenylbenzene)amido]phenyl}carbonyl)-1,2...)
Affinity DataIC50: 20nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225159((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-met...)
Affinity DataIC50: 27nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Rat)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225163((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-met...)
Affinity DataIC50: 30nMAssay Description:Antagonist activity at rat vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225161(1-({4-[(2-chloro-5-fluorobenzene)amido]phenyl}carb...)
Affinity DataIC50: 32nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225163((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-met...)
Affinity DataIC50: 34nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225162((4R)-N-[2-(dimethylamino)ethyl]-1-({4-[(2-phenylbe...)
Affinity DataIC50: 36nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225168(1-({4-[(2-phenylbenzene)amido]phenyl}carbonyl)-1,2...)
Affinity DataIC50: 37nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225163((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-met...)
Affinity DataIC50: 38nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225174(methyl 1-({4-[(2-chloro-5-fluorobenzene)amido]phen...)
Affinity DataIC50: 40nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225171(2-chloro-5-fluoro-N-(2-methoxy-4-{[(4R)-3'-(1H-1,2...)
Affinity DataIC50: 40nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225170(N-[4-({3'-[(methylamino)methyl]-1,2,3,5-tetrahydro...)
Affinity DataIC50: 44nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225162((4R)-N-[2-(dimethylamino)ethyl]-1-({4-[(2-phenylbe...)
Affinity DataIC50: 45nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225166((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-eth...)
Affinity DataIC50: 50nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225163((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-met...)
Affinity DataIC50: 52nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225173((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]phenyl...)
Affinity DataIC50: 53nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225171(2-chloro-5-fluoro-N-(2-methoxy-4-{[(4R)-3'-(1H-1,2...)
Affinity DataIC50: 63nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225166((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-eth...)
Affinity DataIC50: 71nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225161(1-({4-[(2-chloro-5-fluorobenzene)amido]phenyl}carb...)
Affinity DataIC50: 76nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225160(1-({4-[(2-chloro-5-fluorobenzene)amido]-3-methoxyp...)
Affinity DataIC50: 89nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50065115(N-[4-(5H,11H-Benzo[e]pyrrolo[1,2-a][1,4]diazepine-...)
Affinity DataIC50: 91nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225160(1-({4-[(2-chloro-5-fluorobenzene)amido]-3-methoxyp...)
Affinity DataIC50: 92nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225165(2-chloro-5-fluoro-N-(4-{[(4R)-3'-(1H-imidazol-2-yl...)
Affinity DataIC50: 95nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225158(1-({4-[(2-fluorobenzene)amido]phenyl}carbonyl)-1,2...)
Affinity DataIC50: 100nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225175(N-(3-chloro-4-{[3'-(hydroxymethyl)-1,2,3,5-tetrahy...)
Affinity DataIC50: 100nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225173((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]phenyl...)
Affinity DataIC50: 100nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225164(1-({4-[(5-fluoro-2-methylbenzene)amido]-2-methoxyp...)
Affinity DataIC50: 110nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225160(1-({4-[(2-chloro-5-fluorobenzene)amido]-3-methoxyp...)
Affinity DataIC50: 120nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225172(methyl 1-({4-[(2-fluorobenzene)amido]phenyl}carbon...)
Affinity DataIC50: 130nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225164(1-({4-[(5-fluoro-2-methylbenzene)amido]-2-methoxyp...)
Affinity DataIC50: 140nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50065115(N-[4-(5H,11H-Benzo[e]pyrrolo[1,2-a][1,4]diazepine-...)
Affinity DataIC50: 150nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225166((4R)-1-({4-[(2-chloro-5-fluorobenzene)amido]-3-eth...)
Affinity DataIC50: 150nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225167(N-(4-{[3'-(hydroxymethyl)-1,2,3,5-tetrahydrospiro[...)
Affinity DataIC50: 190nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225174(methyl 1-({4-[(2-chloro-5-fluorobenzene)amido]phen...)
Affinity DataIC50: 190nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225174(methyl 1-({4-[(2-chloro-5-fluorobenzene)amido]phen...)
Affinity DataIC50: 200nMAssay Description:Displacement of [3H]Arg-vasopressin from human recombinant vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225169(2-chloro-N-(4-{[(4R)-3'-(4,5-dihydro-1H-imidazol-2...)
Affinity DataIC50: 320nMAssay Description:Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced intracellular calci...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development

Curated by ChEMBL
LigandPNGBDBM50225168(1-({4-[(2-phenylbenzene)amido]phenyl}carbonyl)-1,2...)
Affinity DataIC50: 360nMAssay Description:Antagonist activity at human vasopressin V2 receptor expressed in HEK293 cells assessed as inhibition of Arg-vasopressin-induced cAMP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/11/2009
Entry Details Article
PubMed
Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: